Close Menu

NEW YORK – Veracyte on Tuesday announced preliminary fourth quarter revenue growth of 14 to 18 percent.

The firm has also entered a definitive agreement to acquire San Diego-based urologic cancer test developer Decipher Biosciences for $600 million in cash and stock.

Veracyte said that it expects Q4 revenue of $34.0 to $35.0 million compared to $29.7 million a year ago and above the consensus Wall Street estimate of $31.8 million. The firm expects Q4 product and testing volume of between 13,000 and 13,200 tests.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Science reports that Science Foundation Ireland is seeking annual budget increases.

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Sponsored by

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community. 

Sponsored by

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.